Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Unknown 4Terminated 4Recruiting 3Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 18Thoracic 10Head & Neck 8Lymphoid 4CNS 4Other hematologic neoplasm 3Genitourinary 2Sarcoma 1Other 1Gynecologic 1

Conditions

Prostatic Neoplasms 2966Carcinoma, Renal Cell 882Urinary Bladder Neoplasms 711Kidney Neoplasms 457Breast Neoplasms 408Neoplasms 390Neoplasm Metastasis 229Carcinoma, Non-Small-Cell Lung 229Lung Neoplasms 216Ovarian Neoplasms 211Colorectal Neoplasms 204Melanoma 195Carcinoma, Transitional Cell 190Testicular Neoplasms 171Pancreatic Neoplasms 142Sarcoma 129Head and Neck Neoplasms 121Colonic Neoplasms 120Wilms Tumor 119Uterine Cervical Neoplasms 116Stomach Neoplasms 98Neuroblastoma 90Multiple Myeloma 88Lymphoma, Non-Hodgkin 86Esophageal Neoplasms 86Lymphoma 83Carcinoma, Hepatocellular 81Carcinoma, Ovarian Epithelial 80Recurrence 75Squamous Cell Carcinoma of Head and Neck 74

Interventions

TH 302 13-(4-(2-fluoroethoxy)phenyl)-2-(3-methyl-2-(4-((2-sulfamoylbenzo(d)thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Hypoxia × Genitourinary × Clear all
NCT00743379 2015-05-07

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

Threshold Pharmaceuticals

Phase 1/2 Completed
71 enrolled
GastrointestinalGenitourinaryThoracic

Hypoxia, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Prostatic Neoplasms

NCT00884520 2010-03-16

VM4-037

Siemens Molecular Imaging

Phase EARLY_PHASE1 Completed
16 enrolled
GastrointestinalGenitourinaryHead & NeckThoracic

Hypoxia, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡